Guardant Health, Inc. (NASDAQ:GH) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET

Company Participants

Alex Kleban - Vice President, Investor Relations

Helmy Eltoukhy - Co-Chief Executive Officer

AmirAli Talasaz - Co-Chief Executive Officer

Mike Bell - Chief Financial Officer

Conference Call Participants

Puneet Souda - SVB Securities

Jack Meehan - Nephron Research

Mark Massaro - BTIG

Brian Weinstein - William Blair

Kyle Mikson - Canaccord

Matt Sykes - Goldman Sachs

Daniel Macek - Stifel

David Westenberg - Piper Sandler

Derik De Bruin - Bank of America

Patrick Donnelly - Citi

Operator

Hello and welcome to today's Guardant Health Second Quarter 2022 Financial Results. My name is Bailey, and I will be your moderator for today's call. All lines will be muted during the presentation portion of the call with an opportunity for questions-and-answers at the end. [Operator Instructions]

I would now like to pass the conference over to our host, Alex Kleban. Alex, please go ahead.

Alex Kleban

Thank you. Earlier today, Guardant Health released financial results for the quarter ended June 30 2022. Joining me today from Guardant are Helmy Eltoukhy, Co-CEO; AmirAli Talasaz, Co-CEO; and Mike Bell Chief Financial Officer.

Before we begin, I'd like to remind you that during this call management will make forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled Forward-Looking Statements in the press release Guardant issued today. For a more complete list and description, please see the Risk Factors section of the company's annual report on Form 10-K for the year ended December 31, 2021 and in its other filings with the Securities and Exchange Commission.

This call will also include a discussion of certain financial measures that are not calculated in accordance with GAAP. A Reconciliation to the most directly comparable GAAP financial measures may be found in today's earnings release submitted to the SEC. Except as required by law, Guardant disclaims any intention or obligation to update or revise any financial projections or forward-looking statements whether because of new information, future events or otherwise. This conference call contains time-sensitive information and is accurate only as of live broadcast August 4, 2022.

With that, I'd like to turn the call over to Helmy.

Helmy Eltoukhy

Thanks Alex. Good afternoon and thank you for joining our second quarter 2022 earnings call. I will begin the call today providing an update on our progress across oncology including quarterly trends, reimbursement and upcoming product launches. I will then turn the call over to AmirAli for an update on the Eclipse time line, the Shield LVT launch and multi-cancer screening. And finally, Mike will provide a more detailed look at our financials and guidance for 2022.